Latest news with #JourneyofHealth
Cision Canada
20-05-2025
- Business
- Cision Canada
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /CNW/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at
Yahoo
20-05-2025
- Business
- Yahoo
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at View original content to download multimedia: SOURCE Apotex Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-02-2025
- Business
- Yahoo
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
AACHEN, Germany and TORONTO, Feb. 24, 2025 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain. Under the agreement, Searchlight Pharma ("Searchlight"), Apotex's Specialty Pharma Division, will pursue marketing authorization for Qutenza® and market and distribute Qutenza® in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties. Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities. "We have continuously developed Qutenza® to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US," says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. "Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain." This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 pharmaceutical and consumer health products. "Licensing the Canadian rights to Qutenza® enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets," said Mark Nawacki, President of Searchlight. "This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care." About Qutenza® In Europe, Qutenza® is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group | Instagram: grunenthal About Apotex and Searchlight Pharma Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets. Learn more about us at and at Media Contacts Grünenthal Florian DieckmannHead Global Corporate Affairs Phone: +49 241 569-2555 ApotexMedia, media@ View original content: SOURCE Grünenthal Group Sign in to access your portfolio
